{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025020","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.682811+00:00","generated_at":"2026-05-31T11:52:22.789903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clene Q2 net loss narrows to $6.8M; ALS survival data shows 60% risk reduction vs controls","bullets":["Net loss of $6.8M ($1.06 per share) vs $25.1M ($5.84) in Q2 2023; cash and equivalents $21.7M.","R&D expenses fell to $4.2M from $6.6M, partly due to NIH grant reimbursement for ALS expanded access program.","CNM-Au8 30mg showed ~60% decreased risk of death vs matched PRO-ACT controls up to 3.5 years (HR 0.431, p=0.0002).","Submitted briefing book to FDA for Type C meeting in Q3 2024 to discuss accelerated approval pathway for CNM-Au8 in ALS.","Completed 1-for-20 reverse stock split to regain Nasdaq $1.00 minimum bid price compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025020","json":"https://secwatch.observer/filing/0001437749-24-025020.json","markdown":"https://secwatch.observer/filing/0001437749-24-025020.md","text":"https://secwatch.observer/filing/0001437749-24-025020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924025020/0001437749-24-025020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924025020/clnn20240522_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:52:22.789903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}